Top

Journal of Cardiovascular Translational Research

Published in:

01-02-2014

Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial

Authors: Stefanie Schulz, Dominick J. Angiolillo, David Antoniucci, Isabell Bernlochner, Christian Hamm, Juliane Jaitner, Karl-Ludwig Laugwitz, Katharina Mayer, Barbara von Merzljak, Tanja Morath, Franz-Josef Neumann, Gert Richardt, Judith Ruf, Gisela Schömig, Helmut Schühlen, Heribert Schunkert, Adnan Kastrati, Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators

Published in: Journal of Cardiovascular Translational Research | Issue 1/2014

Abstract

In acute coronary syndromes (ACS), a dual antiplatelet regimen with an adenosine diphosphate (ADP) receptor antagonist plus aspirin has become the cornerstone of treatment. The third-generation thienopyridine prasugrel and the cyclopentyl-triazolo-pyrimidine ticagrelor provide a greater, more rapid and consistent platelet inhibition compared to their predecessor clopidogrel. Based on their advantages over clopidogrel in two landmark studies, both drugs received a class I recommendation for their use in ACS patients with and without ST segment elevation. Due to differences in ACS populations and conditions investigated, the relative merits of ticagrelor versus prasugrel in the treatment of ACS patients with planned invasive strategy cannot be reliably estimated from independent trials. To date, no direct head-to-head comparison of ticagrelor and prasugrel in terms of clinical outcome exists. The aim of this multicenter, randomized, open-label trial is to assess whether ticagrelor is superior to prasugrel in ACS patients with planned invasive strategy.

Available only for authorised users

Schomig, A., Neumann, F. J., Kastrati, A., et al. (1996). A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. The New England Journal of Medicine, 334, 1084–1089.PubMedCrossRef

Hamm, C. W., Bassand, J. P., Agewall, S., et al. (2011). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 32, 2999–3054.PubMedCrossRef

Task Force on the management of STseamiotESoC, Steg, P. G., James, S. K., et al. (2012). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 33, 2569–2619.PubMedCrossRef

Kushner, F. G., Hand, M., Smith, S. C., Jr., et al. (2009). 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 54, 2205–2241.PubMedCrossRef

Levine, G. N., Bates, E. R., Blankenship, J. C., et al. (2011). 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Journal of the American College of Cardiology, 58, e44–e122.PubMedCrossRef

Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O'Connor, C. M. (2003). Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 107, 2908–2913.PubMedCrossRef

Serebruany, V. L., Steinhubl, S. R., Berger, P. B., Malinin, A. I., Bhatt, D. L., & Topol, E. J. (2005). Variability in platelet responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology, 45, 246–251.PubMedCrossRef

Bonello, L., Tantry, U. S., Marcucci, R., et al. (2010). Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. Journal of the American College of Cardiology, 56, 919–933.PubMedCrossRef

Wiviott, S. D., Braunwald, E., McCabe, C. H., et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 357, 2001–2015.PubMedCrossRef

10.

Wallentin, L., Becker, R. C., Budaj, A., et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 361, 1045–1057.PubMedCrossRef

11.

Brandt, J. T., Payne, C. D., Wiviott, S. D., et al. (2007). A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. American Heart Journal, 153(66), 9–16.

12.

Gurbel, P. A., Bliden, K. P., Butler, K., et al. (2009). Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation, 120, 2577–2585.PubMedCrossRef

13.

Sugidachi, A., Asai, F., Ogawa, T., Inoue, T., & Koike, H. (2000). The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. British Journal of Pharmacology, 129, 1439–1446.PubMedCrossRef

14.

Husted, S., Emanuelsson, H., Heptinstall, S., Sandset, P. M., Wickens, M., & Peters, G. (2006). Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. European Heart Journal, 27, 1038–1047.PubMedCrossRef

15.

Wallentin, L. (2009). P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European Heart Journal, 30, 1964–1977.PubMedCrossRef

16.

Schomig, A. (2009). Ticagrelor—is there need for a new player in the antiplatelet-therapy field? The New England Journal of Medicine, 361, 1108–1111.PubMedCrossRef

17.

Steg, P. G., James, S., Harrington, R. A., et al. (2010). Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation, 122, 2131–2141.PubMedCrossRef

18.

Montalescot, G., Wiviott, S. D., Braunwald, E., et al. (2009). Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet, 373, 723–731.PubMedCrossRef

19.

Montalescot, G., Bolognese, L., Dudek, D., et al. (2011). A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. American Heart Journal, 161, 650–656. e1.PubMedCrossRef

20.

Montalescot, G., Bolognese, L., Dudek, D., et al. (2013). Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. New England Journal of Medicine, 369, 999–1010.PubMedCrossRef

21.

Roe, M. T., Armstrong, P. W., Fox, K. A., et al. (2012). Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. The New England Journal of Medicine, 367, 1297–1309.PubMedCrossRef

22.

James, S. K., Roe, M. T., Cannon, C. P., et al. (2011). Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ, 342, d3527.PubMedCentralPubMedCrossRef

23.

Held, C., Asenblad, N., Bassand, J. P., et al. (2011). Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology, 57, 672–684.PubMedCrossRef

24.

Headrick, J. P., Peart, J. N., Reichelt, M. E., & Haseler, L. J. (1808). Adenosine and its receptors in the heart: regulation, retaliation and adaptation. Biochimica et Biophysica Acta, 2011, 1413–1428.

25.

Serebruany, V. L. (2011). Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial? American Heart Journal, 161, 1–4.PubMedCrossRef

26.

Ohman, J., Kudira, R., Albinsson, S., Olde, B., & Erlinge, D. (2012). Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochemical and Biophysical Research Communications, 418, 754–758.PubMedCrossRef

27.

Björkman JA, K. I., & van Giezen, J. J. J. (2007). AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion. Circulation, 116(II), 28. Abstract 245.

28.

van Giezen, J. J., Sidaway, J., Glaves, P., Kirk, I., & Bjorkman, J. A. (2012). Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. Journal of Cardiovascular Pharmacology and Therapeutics, 17, 164–172.PubMedCrossRef

29.

Wittfeldt, A., Emanuelsson, H., Brandrup-Wognsen, G., et al. (2013). Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. Journal of the American College of Cardiology, 61(7), 723–7. doi:10.1016/j.jacc.2012.11.032.PubMedCrossRef

30.

Mehran, R., Rao, S. V., Bhatt, D. L., et al. (2011). Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation, 123, 2736–2747.PubMedCrossRef

31.

Cutlip, D. E., Windecker, S., Mehran, R., et al. (2007). Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 115, 2344–2351.PubMedCrossRef

32.

Thygesen, K., Alpert, J. S., Jaffe, A. S., et al. (2012). Third universal definition of myocardial infarction. European Heart Journal, 33, 2551–2567.PubMedCrossRef

33.

Wiviott, S. D., White, H. D., Ohman, E. M., et al. (2013). Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, 382, 605–613.PubMedCrossRef

34.

Sarafoff, N., Martischnig, A., Wealer, J., et al. (2013). Triple therapy with aspirin, prasugrel, and vitamin k antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. Journal of the American College of Cardiology, 61, 2060–2066.PubMedCrossRef

Title: Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial
Authors: Stefanie Schulz
Dominick J. Angiolillo
David Antoniucci
Isabell Bernlochner
Christian Hamm
Juliane Jaitner
Karl-Ludwig Laugwitz
Katharina Mayer
Barbara von Merzljak
Tanja Morath
Franz-Josef Neumann
Gert Richardt
Judith Ruf
Gisela Schömig
Helmut Schühlen
Heribert Schunkert
Adnan Kastrati
Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators
Publication date: 01-02-2014
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 1/2014
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-013-9527-3

2024 ASCO Annual Meeting

Springer Medicine

Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Non Optical Semi-Conductor Next Generation Sequencing of the Main Cardiac QT-Interval Duration Genes in Pooled DNA Samples

Optimizing Antithrombotic Therapy After Coronary Stent Implantation in Patients on Chronic Oral Anticoagulation

Impact of Cigarette Smoking on P2Y12 Receptor Binding Activity Before and After Clopidogrel Therapy in Patients with Coronary Artery Disease

Impact of Mild Hypothermia on Platelet Responsiveness to Aspirin and Clopidogrel: an In Vitro Pharmacodynamic Investigation

Association of Thrombin Generation Potential with Platelet PAR-1 Regulation and P-Selectin Expression in Patients on Dual Antiplatelet Therapy

Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside